Olema Pharmaceuticals (OLMA) is a clinical-stage biopharmaceutical company with no product revenue. For the year ended December 31, 2025, the company reported a net loss of $162.5M on zero revenue, driving accumulated deficit to $597.6M. Under a liquidation lens, the recovery posture is marginally positive but thin: reported total assets of $533.4M are overwhelmingly liquid, with $48.3M in cash and $505.6M in available-for-sale debt securities (at fair value, amortized cost $505.0M, net unrealized gain of $0.6M), plus $10.0M in prepaid and other current assets. Applying standard haircuts — cash at 100%, AFS securities at approximately 100% given near-zero credit loss allowance and no positions in continuous unrealized loss >12 months, and prepaid/other current at a steep discount — liquidation-recoverable assets approximate $530M-$555M. Liability stack at face value totals $54.9M: current liabilities of $51.8M (accounts payable $9.3M, accrued bonuses $8.3M, other current liabilities $41.4M which likely includes large accrued CRO/clinical trial payables), plus $3.1M in noncurrent items including a $3.0M drawn SVB line of credit (subject to the Third Amendment to Loan and Security Agreement dated January 11, 2026, filed herewith) and a $69K operating lease noncurrent tail. Operating lease total remaining obligation is $1.2M ($1.2M due next 12 months, $69K thereafter), with lease liability already on balance sheet at $1.2M — no material off-balance-sheet lease exposure. Net liquidation recovery to equity is approximately $478M-$500M, broadly consistent with reported book equity of $478.6M, because virtually all assets are already marked near liquidation value. The $41.4M 'other current liabilities' bucket is the primary liability uncertainty — it is not separately broken out in XBRL beyond the aggregate tag, and likely embeds significant accrued clinical trial and CRO obligations. The filing discloses $157.7M in R&D spend for fiscal 2025, suggesting material ongoing CRO commitments that would not fully extinguish at face value on wind-up; this is discussed in MD&A but not separately tagged in XBRL beyond the aggregate OtherLiabilitiesCurrent line. The SVB line of credit ($3.0M drawn, Third Amendment executed January 2026) adds a secured creditor with priority over equity in a liquidation. Prior period (Q3 2025 10-Q) showed similar structure. The December 2024 private placement and 2025 ATM facility substantially rebuilt the liquidity position; the company stated at Q3 2025 that it had approximately $505M in cash and investments. Fiscal 2025 operating cash burn was $146.7M, implying roughly 3+ years of runway at current burn if the investment portfolio is included. No goodwill, no material PP&E ($274K net), and no inventory — the asset mix is nearly entirely cash-equivalent, which is the best-case scenario under a liquidation lens. The DTA of $143.9M carries a full valuation allowance and recovers nothing in liquidation.
▼ Community Notes